In lung adenocarcinoma (LUAD), a prognostic signature of the tumor microenvironment (LATPS) consisting of UBE2T, KRT6A, IRX2 and CD3D has shown that low LATPS is characterized by an immune phenotype, including an increased amount of ICI, tumor immune system dysfunction and increased activity of immune-related pathways, leading to better benefit from immunotherapy [87]. This evidence concerns the gene IRX2 and neoplasm.